Open Access

Prognosis and treatment differences between initial and second primary chondrosarcoma

  • Authors:
    • Weipu Mao
    • Minghao Kong
    • Haiyang Yu
    • Dongyan Wang
    • Xin Huang
    • Xudong Yao
    • Jie Fan
    • Jiang Geng
  • View Affiliations

  • Published online on: May 7, 2019     https://doi.org/10.3892/ol.2019.10329
  • Pages: 207-218
  • Copyright: © Mao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Prognosis and treatment differences between initial and second primary chondrosarcoma (pCS) remain unknown. In the present study, patients with chondrosarcoma diagnosed between January 2004 and December 2015 were identified using the Surveillance Epidemiology and End Results database. Kaplan‑Meier curves and log‑rank tests were used to assess overall survival (OS) and cancer‑specific survival. Univariable and multivariable Cox regression analyses were used to determine factors associated with all‑cause mortality and cancer‑specific mortality. In total, 1,655 eligible patients were included in the cohort of the present study, of which, 1,455 (87.9%) had initial pCS and 200 (12.1%) had second pCS. Patients with second pCS were more frequently diagnosed in the age range of 61‑80 years compared with patients with initial pCS (52.5 vs. 43.1%; P<0.001). The OS rate of patients with initial pCS was significantly higher than that of patients with second pCS (78.3 vs. 63.0%; P<0.001). Multivariable logistic regression analyses suggested that second pCS predicted higher all‑cause mortality (hazard ratio, 1.72; 95% confidence interval, 1.31‑2.26, P<0.001) compared with that in patients with initial pCS. Furthermore, there were no differences observed in the treatment benefits between the patients with initial and second pCS. In conclusion, second pCS was more frequently diagnosed in older patients compared with initial pCS. In addition, the prognosis of patients with second pCS was worse than that of patients with initial pCS, and the treatment is essentially the same for initial and second pCS.

Introduction

Chondrosarcoma is a malignant tumour originating from cartilage tissue and is the second most common malignant bone tumour after osteosarcomas worldwide (1,2). Chondrosarcoma primarily occurs in individuals >50 years of age and, in the majority of cases, affects the limbs and pelvis (3). Pathological types can be divided into conventional intramedullary chondrosarcoma, clear cell chondrosarcoma, mesenchymal chondrosarcoma, juxtacortical chondrosarcoma and myxoid chondrosarcoma (4,5). Chondrosarcoma has a poor response to traditional chemotherapy and radiotherapy, and surgical resection is currently the only successful treatment available (68).

In recent years, second primary cancer types have become more prominent, and the incidence and risk of second primary cancer is increasing in countries such as the USA and the Netherlands (9,10). This increase may be due to a significant improvement in the survival times of those adults with cancer or the use of commonly used cancer treatments such as radiotherapy or chemotherapy (1113). In the present study, second primary chondrosarcoma (pCS) is defined as a tumour that is different in location or histology from the initial pCS and is not derived from the metastasis or recurrence of the initial pCS. Chondrosarcoma rarely presents as a second primary tumour (10).

To the best of our knowledge, no studies have evaluated the prognosis or treatment differences between the initial pCS and the second pCS thus far. The purpose of the present study was to analyse the difference in prognosis between the initial and second pCS, and the difference in treatment outcomes on the basis of a population-level study of chondrosarcoma.

Materials and methods

Data source and patients

The Surveillance Epidemiology and End Results (SEER) database (https://seer.cancer.gov/) of the National Cancer Institute (Bethesda, MD, USA) was used as the data source in the present study. In total, 3,055 patients with initial and second pCS were identified using the International Classification of Diseases for Oncology (ICD-O-3) (http://codes.iarc.fr/) histology codes 9220/3,9221/3,9231/3,9240/3,9242/3 and 9243/3. The patients had been diagnosed between January 1, 2004, and December 31, 2015. SEER*Stat software (version 8.3.5; National Cancer Institute) was used to access the SEER 18 Regs Custom Data (with an additional treatment field) Nov 2017 Sub (1973–2015 varying) database using the client-server mode of SEER*Stat. Patients with unknown survival time, unknown American Joint Committee on Cancer (AJCC) stage or unknown Tumour-Node-Metastasis (TNM) stage (14), as well as those diagnosed at autopsy, <18 years of age or having a non-initial visit to hospital and non-osteoarticular chondrosarcoma were excluded. The National Cancer Institute's SEER database covers ~30% of the population in the USA, and collects information such as demographics, tumour histology, tumour stage at diagnosis, treatment information and survival time (15). Finally, 1,655 eligible patients were identified.

The second pCS may be synchronous or metachronous. The definitions of the second pCS met the following criteria: i) Synchronous cancer is a second pCS diagnosed simultaneously or within 6 months of diagnosis of the initial pCS (9); ii) metachronous cancer is a diagnosis of second pCS ≥6 months following the diagnosis of an initial pCS; iii) the primary site differs between the initial pCS and the second pCS; iv) histology is different if the primary site is the same as the primary site of the initial primary cancer.

Study variables

Overall survival (OS) and cancer-specific survival (CSS) were the primary outcomes in the present study. The patients in the present study were categorized into two groups: Initial pCS and second pCS. The following variables were extracted for analysis: Year of diagnosis, age at diagnosis, sex, ethnicity, marital status, area of geographical state, urban-rural residence, laterality, primary site, tumour grade, histological type, AJCC stage, extent of disease (for T and M stages), regional nodes positive (for N stage) and treatment methods (surgery, radiotherapy or chemotherapy).

Statistical analysis

The baseline data of demographics and clinicopathological characteristics of the initial and second pCS were compared using χ2 tests. Kaplan-Meier curves and log-rank tests were used for OS and CSS. Univariable analysis was performed using the log-rank test to determine the factors associated with all-cause mortality and cancer-specific mortality. Furthermore, univariable and multivariable Cox regression analyses were used to determine the factors associated with all-cause mortality and cancer-specific mortality. All statistical analyses were performed using SPSS statistics software (version 20; IBM Corp., Armonk, NY, USA). P≤0.05 was considered to indicate a statistically significant result.

Results

Demographic and clinical characteristics of the initial and second pCS

In total, 1,655 eligible patients with chondrosarcoma who were diagnosed between January 1, 2004, and December 31, 2015, were included in the cohort of the present study, with data obtained from the SEER database between January 1, 2004, and December 31, 2015. Among them, 1,455 (87.9%) patients had initial pCS and 200 (12.1%) patients had second pCS. The clinical characteristics and the χ2 test for comparison of the initial and second pCS are presented in Table I. The data presented in Table I indicates that the incidence of chondrosarcoma increases with the year of diagnosis. χ2 test revealed significant differences between the initial and second pCS in certain variables, including year of diagnosis (P=0.048), age at diagnosis (P<0.001), tumour AJCC stage (P=0.024) and M-stage (P=0.044). Patients with second pCS were more frequently diagnosed at 61–80 years of age (52.5 vs. 43.1%; P<0.001) compared with patients with initial pCS. Furthermore, the majority of patients with initial and second pCS chose to receive surgical treatment (92.0 and 91.0% respectively), and markedly less patients chose to receive radiotherapy (14.8 and 15.0%, respectively) or chemotherapy (8.0 vs. 5.5%, respectively).

Table I.

Characteristics of patients stratified by initial and second pCS.

Table I.

Characteristics of patients stratified by initial and second pCS.

CharacteristicsAll patientsInitial pCSSecond pCSP-value
Total, n (%)1,6551,455 (87.9)200 (12.1)
Median survival, months41.0042.0034.50
Year of diagnosis, n (%) 0.048
  2004–2006343 (20.7)299 (20.5)44 (22.0)
  2007–2009399 (24.1)363 (24.9)36 (18.0)
  2010–2012427 (25.8)362 (24.9)65 (32.5)
  2013–2015486 (29.4)431 (29.6)55 (27.5)
Age at diagnosis in years, n (%) <0.001
  18–40392 (23.7)382 (26.3)10 (5.0)
  41–60691 (41.8)627 (43.1)64 (32.0)
  61–80490 (29.6)385 (26.5)105 (52.5)
  >8082 (5.0)61 (4.2)21 (10.5)
Sex, n (%) 0.724
  Female742 (44.8)650 (44.7)92 (46.0)
  Male913 (55.2)805 (55.3)108 (54.0)
Ethnicity, n (%) 0.882
  Caucasian1,444 (87.3)1,269 (87.2)175 (87.5)
  African-American111 (6.7)99 (6.8)12 (6.0)
  Other100 (6.0)87 (6.0)13 (6.5)
Marital status, n (%) 0.265
  Married957 (57.8)831 (57.1)126 (63.0)
  Single622 (37.6)555 (38.1)67 (33.5)
  Unknown76 (4.6)69 (4.7)7 (3.5)
State, n (%) 0.751
  West875 (52.9)763 (52.4)112 (56.0)
  Northeast300 (18.1)267 (18.4)33 (16.5)
  South334 (20.2)294 (20.2)40 (20.0)
  Midwest146 (8.8)131 (9.0)15 (7.5)
Urban-rural residence, n (%) 0.650
  Metropolitan1,472 (88.9)1,296 (89.1)176 (88.0)
  Non-metropolitan183 (11.1)159 (10.9)24 (12.0)
Laterality, n (%) 0.907
  Left633 (38.2)554 (38.1)79 (39.5)
  Right676 (40.8)597 (41.0)79 (39.5)
  Other346 (20.9)304 (20.9)42 (21.0)
Primary site, n (%) 0.542
  Appendicular803 (48.5)710 (48.8)93 (46.5)
  Axial852 (51.5)745 (51.2)107 (53.5)
Grade, n (%) 0.505
  Well-differentiated575 (34.7)513 (35.3)62 (31.0)
  Moderately differentiated684 (41.3)603 (41.5)81 (40.5)
  Poorly differentiated230 (13.9)198 (13.6)32 (16.0)
  Undifferentiated141 (8.5)119 (8.2)22 (11.0)
  Unknown25 (1.5)22 (1.5)3 (1.5)
Histological type, n (%) 0.633
  Chondrosarcoma, NOS1,353 (81.8)1,191 (81.9)162 (81.0)
  Juxtacortical chondrosarcoma21 (1.3)19 (1.3)2 (1.0)
  Myxoid chondrosarcoma102 (6.2)93 (6.4)9 (4.5)
  Mesenchymal chondrosarcoma18 (1.1)16 (1.1)2 (1.0)
  Clear cell chondrosarcoma11 (0.7)10 (0.7)1 (0.5)
  Dedifferentiated chondrosarcoma150 (9.1)126 (8.7)24 (12.0)
AJCC stage, n (%) 0.024
  I1,213 (73.3)1,072 (73.7)141 (70.5)
  II307 (18.5)257 (17.7)50 (25.0)
  III18 (1.1)16 (1.1)2 (1.0)
  IV117 (7.1)110 (7.6)7 (3.5)
T-stage, n (%) 0.593
  T11,020 (61.6)903 (62.1)117 (58.5)
  T2608 (36.7)528 (36.3)80 (40.0)
  T327 (1.6)24 (1.6)3 (1.5)
N-stage, n (%) 0.359
  N01,636 (98.9)1,437 (98.8)199 (99.5)
  N119 (1.1)18 (1.2)1 (0.5)
M-stage, n (%) 0.044
  M01,552 (93.8)1,358 (93.3)194 (97.0)
  M1103 (6.2)97 (6.7)6 (3.0)
Surgery, n (%) 0.617
  No134 (8.1)116 (8.0)18 (9.0)
  Yes1,521 (91.9)1,339 (92.0)182 (91.0)
Radiotherapy, n (%) 0.934
  No1,410 (85.2)1,240 (85.2)170 (85.0)
  Yes245 (14.8)215 (14.8)30 (15.0)
Chemotherapy, n (%) 0.207
  No1,527 (92.3)1,338 (92.0)189 (94.5)
  Yes128 (7.7)117 (8.0)11 (5.5)

[i] Percentages may not total 100 due to rounding. AJCC, American Joint Committee on Cancer; pCS, primary chondrosarcoma; NOS, not otherwise specified.

Univariate survival analyses of factors associated with all-cause mortality and cancer-specific mortality

Univariate survival analyses of patients with initial and second pCS according to various clinicopathological variables (Table II). Among the 1,655 initial and second pCS patients, 390 (23.6%) were categorized as cases of all-cause mortality and 228 (13.8%) succumbed to chondrosarcoma. Univariate analyses revealed that year of diagnosis, age at diagnosis, sex, tumour grade, histological type, AJCC stage, TNM stage, surgery, radiotherapy and chemotherapy were associated with all-cause mortality and chondrosarcoma-associated mortality (all P<0.05). In addition, patients with second pCS had a higher rate of all-cause mortality compared with patients with initial pCS (P<0.001), but there was no significant difference between initial and second pCS in terms of chondrosarcoma-associated mortality (P=0.734).

Table II.

Univariate survival analyses of the 1,655 patients with chondrosarcoma according to various clinicopathological variables.

Table II.

Univariate survival analyses of the 1,655 patients with chondrosarcoma according to various clinicopathological variables.

All-cause Chondrosarcoma-associated


CharacteristicsSuccumbed, n (%)Alive, n (%)P-valueSuccumbed, n (%)aCensored, n (%)P-value
Total patients in study390 (23.6)1,265 (76.4) 228 (13.8)1,427 (86.2)
Year of diagnosis <0.001 <0.001
  2004–2006120 (30.8)223 (17.6) 68 (29.8)275 (19.3)
  2007–2009109 (27.9)290 (22.9) 62 (27.2)337 (23.6)
  2010–2012109 (27.9)318 (25.1) 69 (30.3)358 (25.1)
  2013–201552 (13.3)434 (34.3) 29 (12.7)457 (32.0)
Age at diagnosis, years <0.001 <0.001
  18–4038 (9.7)354 (28.0) 27 (11.8)365 (25.6)
  41–60142 (36.4)549 (43.4) 92 (40.4)599 (42.0)
  61–80167 (42.8)323 (25.5) 93 (40.8)397 (27.8)
  >8043 (11.0)39 (3.1) 16 (7.0)66 (4.6)
Sex <0.001 0.041
  Female144 (36.9)598 (47.3) 88 (38.6)654 (45.8)
  Male246 (63.1)667 (52.7) 140 (61.4)773 (54.2)
Ethnicity 0.390 0.862
  Caucasian339 (86.9)1,105 (87.4) 201 (88.2)1,243 (87.1)
  African-American31 (7.9)80 (6.3) 15 (6.6)96 (6.7)
  Other20 (5.1)80 (6.3) 12 (5.3)88 (6.2)
Marital status 0.352 0.491
  Married220 (56.4)737 (58.3) 135 (59.2)822 (57.6)
  Single156 (40.0)466 (36.8) 86 (37.7)536 (37.6)
  Unknown14 (3.6)62 (4.9) 7 (3.1)69 (4.8)
State 0.469 0.309
  West209 (53.6)666 (52.6) 129 (56.6)746 (52.3)
  Northeast65 (16.7)235 (18.6) 35 (15.4)265 (18.6)
  South75 (19.2)259 (20.5) 40 (17.5)294 (20.6)
  Midwest41 (10.5)105 (8.3) 24 (10.5)122 (8.5)
Urban-rural residence 0.836 0.684
  Metropolitan348 (89.2)1,124 (88.9) 201 (88.2)1,271 (89.1)
  Non-metropolitan42 (10.8)141 (11.1) 27 (11.8)156 (10.9)
Laterality 0.941 0.224
  Left152 (39.0)481 (38.0) 94 (41.2)539 (37.8)
  Right158 (40.5)518 (40.9) 96 (42.1)580 (40.6)
  Other80 (20.5)266 (21.0) 38 (16.7)308 (21.6)
Primary site 0.887 0.532
  Appendicular188 (48.2)615 (48.6) 115 (50.4)688 (48.2)
  Axial202 (51.8)650 (51.4) 113 (49.6)739 (51.8)
Grade <0.001 <0.001
  Well-differentiated61 (15.6)514 (40.6) 26 (11.4)549 (38.5)
  Moderately differentiated133 (34.1)551 (43.6) 76 (33.3)608 (42.6)
  Poorly differentiated87 (22.3)143 (11.3) 56 (24.6)174 (12.2)
  Undifferentiated89 (22.8)52 (4.1) 60 (26.3)81 (5.7)
  Unknown20 (5.1)5 (0.4) 10 (4.4)15 (1.1)
Histological type <0.001 <0.001
  Chondrosarcoma, NOS242 (62.1)1,111 (87.7) 137 (60.1)1,216 (85.2)
  Juxtacortical chondrosarcoma2 (0.5)19 (1.5) 2 (0.9)19 (1.3)
  Myxoid chondrosarcoma29 (7.4)73 (5.8) 20 (8.8)82 (5.7)
  Mesenchymal chondrosarcoma10 (2.6)8 (0.6) 7 (3.1)11 (0.8)
  Clear cell chondrosarcoma3 (0.8)8 (0.6) 0 (0.0)11 (0.8)
  Dedifferentiated chondrosarcoma104 (26.7)46 (3.6) 62 (27.2)88 (6.2)
AJCC stage <0.001 <0.001
  I164 (42.1)1,049 (82.9) 75 (32.9)1,138 (79.7)
  II126 (32.3)181 (14.3) 78 (34.2)229 (16.0)
  III6 (1.5)12 (0.9) 3 (1.3)15 (1.1)
  IV94 (24.1)23 (1.8) 72 (31.6)45 (3.2)
T-stage <0.001 <0.001
  T1151 (38.7)869 (68.7) 80 (35.1)940 (65.9)
  T2226 (57.9)382 (30.2) 141 (61.8)467 (32.7)
  T313 (3.3)14 (1.1) 7 (3.1)20 (1.4)
N-stage <0.001 <0.001
  N0378 (96.9)1,258 (99.4) 220 (96.5)1,416 (99.2)
  N112 (3.1)7 (0.6) 8 (3.5)11 (0.8)
M-stage <0.001 <0.001
  M0304 (77.9)1,248 (98.7) 161 (70.6)1,391 (97.5)
  M186 (22.1)17 (1.3) 67 (29.4)36 (2.5)
Surgery <0.001 <0.001
  No74 (19.0)60 (4.7) 44 (19.3)90 (6.3)
  Yes316 (81.0)1,205 (95.3) 184 (80.7)1,337 (93.7)
Radiotherapy <0.001 <0.001
  No293 (75.1)1,117 (88.3) 166 (72.8)1,224 (87.2)
  Yes97 (24.9)148 (11.7) 62 (27.2)183 (12.8)
Chemotherapy <0.001 <0.001
  No308 (79.0)1,219 (96.4) 170 (74.6)1,357 (95.1)
  Yes82 (21.0)46 (3.6) 58 (25.4)70 (4.9)
Group <0.001 0.734
  Initial pCS316 (81.0)1,139 (90.0) 202 (88.6)1,253 (87.8)
  Second pCS74 (19.0)126 (10.0) 26 (11.4)174 (12.2)

a Includes those patients that succumbed to causes other than chondrosarcoma and those that were still alive. Percentages may not total 100 due to rounding. AJCC, American Joint Committee on Cancer; pCS, primary chondrosarcoma; NOS, not otherwise specified; T, tumor; N, node; M, metastasis.

Survival

The median survival time among the entire cohort was 41.00 months, with patients with initial pCS experiencing a longer median survival time (42.00 months), and patients with second pCS experiencing a shorter median survival time (34.50 months). Fig. 1A presents the OS and CSS of the initial and second pCS. The OS rate of patients with initial pCS was significantly higher compared with that of the patients with second pCS (log-rank test, P<0.001), but the CSS rate of the patients with initial pCS was not significantly different from that of the patients with second pCS (log-rank test, P=0.428). In addition, it was also revealed that among the pathological types of chondrosarcoma, dedifferentiated chondrsarcoma exhibited the worst OS and CSS rates (Fig. 1B). Patients were stratified by primary sites and laterality, and in doing so, it was revealed that the OS rate of the patients with initial pCS was also higher compared with that of the patients with second pCS. However, there was no significant difference between the initial and second pCS in terms of chondrosarcoma-associated mortality (Fig. 2).

Risk factors for all-cause mortality and cancer-specific mortality

Univariate and multivariate Cox regression were used to analyse the factors associated with all-cause mortality and cancer-specific mortality (Table III). Age at diagnosis, sex, histological type, AJCC stage, T stage, surgery and radiotherapy were associated with all-cause mortality and chondrosarcoma-cause mortality (all P<0.05) in univariate and multivariate Cox regression. In the multivariate Cox regression analysis among patients with initial and second pCS, age 41–60 years [vs. age 18–40 years; HR, 1.80; 95% confidence interval (CI), 1.22–2.65; P=0.003], age 61–80 years (vs. age 18–40 years; HR, 2.91; 95% CI, 1.97–4.30; P<0.001), age >80 years (vs. age 18–40 years; HR, 4.04; 95% CI, 2.49–6.57; P<0.001), male (vs. female; HR, 1.50; 95% CI, 1.21–1.85; P<0.001), moderately differentiated (vs. well-differentiated; HR, 1.41; 95% CI, 1.03–1.93; P=0.033), undifferentiated (vs. well-differentiated; HR, 2.00; 95% CI, 1.09–3.68; P=0.026), mesenchymal chondrosarcoma (vs. chondrosarcoma, NOS; HR, 2.11; 95% CI, 1.03–4.33; P=0.042), dedifferentiated chondrosarcoma (vs. chondrosarcoma, NOS; HR, 3.00; 95% CI, 2.20–4.08; P<0.001), AJCC stage IV (vs. AJCC stage I; HR, 5.67; 95% CI, 3.64–8.82; P<0.001), T2 stage (vs. T1 stage; HR, 1.81; 95% CI, 1.46–2.25; P<0.001), surgery (vs. no surgery; HR, 0.39; 95% CI, 0.29–0.52; P<0.001), radiotherapy (vs. no radiotherapy; HR, 1.31; 95% CI, 1.03–1.67; P=0.030) and second pCS (vs. initial pCS; HR, 1.72; 95% CI, 1.31–2.26; P<0.001) were associated with a significant increase in all-cause mortality. However, initial and second pCS were still not associated with improved chondrosarcoma-associated survival on multivariable survival analysis (P=0.294).

Table III.

Risk factors for survival: Outcome is all-cause mortality and cancer-specific mortality.

Table III.

Risk factors for survival: Outcome is all-cause mortality and cancer-specific mortality.

All-cause mortalityCancer-specific mortality


Univariate Cox regressionMultivariate Cox regressionUnivariate Cox regressionMultivariate Cox regression




CharacteristicsHazard ratio (95% CI)P-valueHazard ratio (95% CI)P-valueHazard ratio (95% CI)P-valueHazard ratio (95% CI)P-value
Age at diagnosis, years
  18–40Reference Reference Reference Reference
  41–602.34 (1.63–3.34)<0.0011.80 (1.22–2.65)0.0032.16 (1.41–3.32)<0.0011.86 (1.14–3.02)0.013
  61–804.47 (3.14–6.35)<0.0012.91 (1.97–4.30)<0.0013.77 (2.45–5.78)<0.0012.79 (1.71–4.56)<0.001
  >808.52 (5.50–13.21)<0.0014.04 (2.49–6.57)<0.0015.60 (3.01–10.39)<0.0013.50 (1.81–6.80)<0.001
Sex
  FemaleReference Reference Reference Reference
  Male1.46 (1.19–1.80)<0.0011.50 (1.21–1.85)<0.0011.40 (1.07–1.83)0.0141.40 (1.06–1.85)0.017
Grade
  Well-differentiatedReference Reference Reference Reference
  Moderately differentiated1.95 (1.44–2.64)<0.0011.41 (1.03–1.93)0.0332.65 (1.69–4.13)<0.001NA0.128
  Poorly differentiated4.51 (3.25–6.26)<0.0011.51 (0.84–2.71)0.1697.14 (4.49–11.38)<0.001NA0.532
  Undifferentiated10.62 (7.65–14.73)<0.0012.00 (1.09–3.68)0.02617.51 (11.04–27.78)<0.001NA0.297
  Unknown15.53 (9.34–25.82)<0.0010.95 (0.49–1.85)0.87825.74 (12.37–53.56)<0.001NA0.583
Histological type
  Chondrosarcoma, NOSReference Reference Reference Reference
  Juxtacortical chondrosarcoma0.51 (0.13–2.04)0.3400.71 (0.18–2.90)0.6360.86 (0.21–3.47)0.8301.10 (0.27–4.50)0.900
  Myxoid chondrosarcoma1.61 (1.09–2.36)0.0161.19 (0.80–1.76)0.4002.02 (1.26–3.23)0.0031.72 (1.06–2.77)0.027
  Mesenchymal chondrosarcoma3.61 (1.92–6.80)<0.0012.11 (1.03–4.33)0.0424.74 (2.22–10.14)<0.0012.37 (0.97–5.80)0.058
  Clear cell chondrosarcoma1.45 (0.46–4.53)0.5231.72 (0.54–5.45)0.360NANANANA
  Dedifferentiated chondrosarcoma7.84 (6.21–9.92)<0.0013.00 (2.20–4.08)<0.0019.68 (7.14–13.13)<0.0013.43 (2.41–4.87)<0.001
AJCC stage
  IReference Reference Reference Reference
  II3.90 (3.09–4.92)<0.0011.53 (0.89–2.61)0.1245.49 (4.00–7.54)<0.0012.91 (2.03–4.16)<0.001
  III2.46 (1.09–5.55)0.0311.11 (0.35–3.53)0.8632.86 (0.90–9.08)0.0741.98 (0.42–9.34)0.391
  IV14.12 (10.88–18.32)<0.0015.67 (3.64–8.82)<0.00124.47 (17.57–34.09)<0.0014.26 (1.69–10.79)0.002
T-stage
  T1Reference Reference Reference Reference
  T23.13 (2.54–3.85)<0.0011.81 (1.46–2.25)<0.0013.82 (2.91–5.03)<0.0011.94 (1.44–2.60)<0.001
  T34.03 (2.29–7.11)<0.0012.20 (0.98–4.90)0.0554.40 (2.03–9.53)<0.0011.43 (0.50–4.10)0.502
N-stage
  N0Reference Reference Reference Reference
  N13.95 (2.22–7.03)<0.001NA0.1675.19 (2.56–10.52)<0.001NA0.260
M-stage
  M0Reference Reference Reference Reference
  M110.69 (8.33–13.71)<0.001NA0.08515.86 (11.79–21.34)<0.0013.13 (1.23–7.99)0.017
Surgery
  NoReference Reference Reference Reference
  Yes0.25 (0.19–0.32)<0.0010.39 (0.29–0.52)<0.0010.22 (0.16–0.30)<0.0010.54 (0.36–0.81)0.003
Radiotherapy
  NoReference Reference Reference Reference
  Yes2.16 (1.71–2.71)<0.0011.31 (1.03–1.67)0.0302.53 (1.89–3.39)<0.0011.47 (1.08–2.01)0.015
Chemotherapy
  NoReference Reference Reference Reference
  Yes4.44 (3.47–5.67)<0.001NA0.9436.19 (4.58–8.35)<0.001NA0.827
Group
  Initial pCSReference Reference Reference Reference
  Second pCS1.87 (1.45–2.41)<0.0011.72 (1.31–2.26)<0.0011.18 (0.78–1.77)0.429NA0.294

[i] AJCC, American Joint Committee on Cancer; CI, confidence interval; NA, not applicable; pCS, primary chondrosarcoma; NOS, not otherwise specified.

Benefits of different treatment for initial and second pCS

To analyse the benefit of different treatments for all-cause mortality, patients with initial and second pCS were stratified by primary site and laterality, and multivariate analysis was used. For patients with appendicular or axial chondrosarcoma, those with initial and second pCS who underwent surgery had lower all-cause mortality (all P<0.05; Fig. 3A) compared with patients who did not receive surgery (Fig. 3A). Similarly, for left-sided or right-sided chondrosarcoma patients, those with initial and second pCS who underwent surgery had lower all-cause mortality rate (all P<0.05) compared with patients without surgery. However, the use of radiotherapy or chemotherapy did not reduce the all-cause mortality rate (Fig. 3B and C).

Discussion

The incidence of chondrosarcoma accounts for ~20% of all primary bone sarcomas (16). Above the age of 40 years, the incidence rate of chondrosarcoma gradually increases, and the incidence rate in men is higher than that in women. Rozeman et al (17) reported that common types of chondrosarcoma accounted for 85% of cases, dedifferentiation for 10%, interstitial type for 2% and clear cell type for 1%. Giuffrida et al (18) analysed 2,890 cases of chondrosarcoma between 1973 and 2003, and revealed that the highest 5-year survival rate was that of clear cell type chondrosarcoma (100%), followed by common chondrosarcoma (70%), and the lowest was that of dedifferentiated chondrosarcoma (0%). The results from the present study also revealed that dedifferentiated chondrosarcoma has the worst prognosis.

Second pCS is a rare occurrence, and, to the best of our knowledge, there are currently no studies that have assessed the prognosis and treatment differences between the initial pCS and the second pCS. Therefore, the present study is the first to report differences in prognosis and treatment between initial pCS and the second pCS.

The present study revealed that the proportion of the four age stages (18–40, 41–60, 61–80 and >80 years) of the patients with initial pCS were 26.3, 43.1, 26.5 and 4.2%, respectively, while the proportion of the patients with second pCS in the four age stages was 5.0,32.0,52.5 and 10.5%, respectively. It was demonstrated that patients with second pCS were at an older age when diagnosed compared with patients with initial pCS. The difference may be due to a significant improvement in survival for patients with cancer.

As one of the multiple primary malignancies (MPMs), the second primary cancer has received greater attention. MPMs are rarely encountered in different organs and tissues in the same patient, and the incidence of MPMs ranges from 0.7–11.0%, as determined through the statistical analysis of several national cancer registries (10,19,20). The most common subsequent types of cancer are squamous cell skin cancer, colorectal cancer and breast cancer (13). Patients with MPMs exhibit a worse 5-year OS rate compared with patients with a single malignancy (21). This may be associated with genetic, environmental and immunological factors, as well as the application of radiotherapy or chemotherapy (22,23).

The risk of developing a subsequent cancer in patients with MPMs was 1.4 to 3.0 times higher compared to the general population (13). There are a number of studies that have focused on second primary tumours. By investigating 2,462 patients with hepatocellular carcinoma who underwent liver transplantation, Heo et al (24) revealed that patients with hepatocellular carcinoma who had received a liver transplantation had a longer life expectancy and higher risk of second primary cancer compared with the general population (standardized incidence ratios, 2.79; 95% CI, 2.27–3.38). Chen et al (25) demonstrated that the prognosis of patients with second primary colorectal cancer was worse than that of patients with initial primary colorectal cancer, and the therapeutic benefit on colorectal cancer prognosis was generally similar for the patients with initial and second primary colorectal cancer. The present study revealed similar results; it was identified that patients with second pCS had a worse prognosis compared with patients with initial pCS, and the treatment benefits were similar for patients with initial and second pCS. Surgery can significantly reduce all-cause mortality, while the use of radiotherapy or chemotherapy does not reduce all-cause mortality.

Furthermore, in terms of demographic and clinical characteristics, χ2 tests revealed a significant difference in the age at diagnosis for patients with initial pCS and those patients with second pCS; patients with second pCS were diagnosed at an older age compared with patients with initial pCS.

The present study does have certain limitations. First, the research is based on the SEER database, a retrospective dataset that therefore has inherent limitations. Secondly, the patients’ physical condition was unclear; patients with excessive comorbidities may pursue more conservative treatment. In addition, the number of patients included in the present study was small, so further prospective studies are necessary.

The results of the present study revealed that patients with second pCS were more frequently diagnosed at an older age and had a worse prognosis compared with patients with initial pCS. For patients with initial and second pCS, surgery was the main treatment method.

Acknowledgements

Not applicable.

Funding

The present study was supported by grant from the Tongji University (grant no. 1501219143) and the National Natural Science Foundation of China (grant no. 81001134.

Availability of data and materials

All the data generated or analyzed during the present study are included in this published article.

Authors' contributions

WM, JF and JG designed the research. HY and MK acquired the data. DW, XH and XY analyzed the results. WM wrote the article. JF and JG revised and provided critical comments. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1 

Wagner MJ, Ricciotti RW, Mantilla J, Loggers ET, Pollack SM and Cranmer LD: Response to PD1 inhibition in conventional chondrosarcoma. J Immunother Cancer. 6:942018. View Article : Google Scholar : PubMed/NCBI

2 

Chen JC, Huang C, Lee IN, Wu YP and Tang CH: Amphiregulin enhances cell migration and resistance to doxorubicin in chondrosarcoma cells through the MAPK pathway. Mol Carcinog. 57:1816–1824. 2018. View Article : Google Scholar : PubMed/NCBI

3 

Sangma MM and Dasiah S: Chondrosarcoma of a rib. Int J Surg Case Rep. 10:126–128. 2015. View Article : Google Scholar : PubMed/NCBI

4 

Murphey MD, Walker EA, Wilson AJ, Kransdorf MJ, Temple HT and Gannon FH: From the archives of the AFIP: Imaging of primary chondrosarcoma: Radiologic-pathologic correlation. Radiographics. 23:1245–1278. 2003. View Article : Google Scholar : PubMed/NCBI

5 

Aigner T: Towards a new understanding and classification of chondrogenic neoplasias of the skeleton-biochemistry and cell biology of chondrosarcoma and its variants. Virchows Arch. 441:219–230. 2002. View Article : Google Scholar : PubMed/NCBI

6 

Schoenfeld AJ, Hornicek FJ, Pedlow FX, Kobayashi W, Raskin KA, Springfield D, DeLaney TF, Nielsen GP, Mankin HJ and Schwab JH: Chondrosarcoma of the mobile spine: A review of 21 cases treated at a single center. Spine (Phila Pa 1976). 37:119–126. 2012. View Article : Google Scholar : PubMed/NCBI

7 

Staals EL, Bacchini P and Bertoni F: Dedifferentiated central chondrosarcoma. Cancer. 106:2682–2691. 2006. View Article : Google Scholar : PubMed/NCBI

8 

Grimer RJ, Gosheger G, Taminiau A, Biau D, Matejovsky Z, Kollender Y, San-Julian M, Gherlinzoni F and Ferrari C: Dedifferentiated chondrosarcoma: Prognostic factors and outcome from a European group. Eur J Cancer. 43:2060–2065. 2007. View Article : Google Scholar : PubMed/NCBI

9 

Siegel RL, Miller KD and Jemal A: Cancer statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI

10 

Liu L, de Vries E, Louwman M, Aben K, Janssen-Heijnen M, Brink M, Coebergh JW and Soerjomataram I: Prevalence of multiple malignancies in the Netherlands in 2007. Int J Cancer. 128:1659–1667. 2011. View Article : Google Scholar : PubMed/NCBI

11 

Cheng HY, Chu CH, Chang WH, Hsu TC, Lin SC, Liu CC, Yang AM and Shih SC: Clinical analysis of multiple primary malignancies in the digestive system: A hospital-based study. World J Gastroenterol. 11:4215–4219. 2005. View Article : Google Scholar : PubMed/NCBI

12 

Chrouser K, Leibovich B, Bergstralh E, Zincke H and Blute M: Bladder cancer risk following primary and adjuvant external beam radiation for prostate cancer. J Urol. 174:107–110. 2005. View Article : Google Scholar : PubMed/NCBI

13 

Brumback RA, Gerber JE, Hicks DG and Strauchen JA: Adenocarcinoma of the stomach following irradiation and chemotherapy for lymphoma in young patients. Cancer. 54:994–998. 1984. View Article : Google Scholar : PubMed/NCBI

14 

Frederick LG, Carolyn CC, April G. Fritz CTR, Jatin PS and David PW: AJCC Cancer Staging Atlas. Springer Berlin. 2012.

15 

Martin AM, Cagney DN, Catalano PJ, Warren LE, Bellon JR, Punglia RS, Claus EB, Lee EQ, Wen PY, Haas-Kogan DA, et al: Brain metastases in newly diagnosed breast cancer: A population-based study. JAMA Oncol. 3:1069–1077. 2017. View Article : Google Scholar : PubMed/NCBI

16 

Fromm J, Klein A, Baur-Melnyk A, Knösel T, Lindner L, Birkenmaier C, Roeder F, Jansson V and Dürr HR: Survival and prognostic factors in conventional central chondrosarcoma. BMC Cancer. 18:8492018. View Article : Google Scholar : PubMed/NCBI

17 

Rozeman LB, Hogendoorn PC and Bovee JV: Diagnosis and prognosis of chondrosarcoma of bone. Expert Rev Mol Diagn. 2:461–472. 2002. View Article : Google Scholar : PubMed/NCBI

18 

Giuffrida AY, Burgueno JE, Koniaris LG, Gutierrez JC, Duncan R and Scully SP: Chondrosarcoma in the United States (1973 to 2003): An analysis of 2890 cases from the SEER database. J Bone Joint Surg Am. 91:1063–1072. 2009. View Article : Google Scholar : PubMed/NCBI

19 

Savary M, Monnier P, Pasche R, Brossard E, Pasche P and Lang F: Multiple primary malignancies. Adv Otorhinolaryngol. 46:165–175. 1991.PubMed/NCBI

20 

Armstrong GT, Liu W, Leisenring W, Yasui Y, Hammond S, Bhatia S, Neglia JP, Stovall M, Srivastava D and Robison LL: Occurrence of multiple subsequent neoplasms in long-term survivors of childhood cancer: A report from the childhood cancer survivor study. J Clin Oncol. 29:3056–3064. 2011. View Article : Google Scholar : PubMed/NCBI

21 

Rosso S, De Angelis R, Ciccolallo L, Carrani E, Soerjomataram I, Grande E, Zigon G and Brenner H; EUROCARE Working Group, : Multiple tumours in survival estimates. Eur J Cancer. 45:1080–1094. 2009. View Article : Google Scholar : PubMed/NCBI

22 

Keller U, Grabenbauer G, Kuechler A, Sprung CN, Müller E, Sauer R and Distel L: Cytogenetic instability in young patients with multiple primary cancers. Cancer Genet Cytogenet. 157:25–32. 2005. View Article : Google Scholar : PubMed/NCBI

23 

Crocetti E, Buiatti E and Falini P; Italian Multiple Primary Cancer Working Group, : Multiple primary cancer incidence in Italy. Eur J Cancer. 37:2449–2456. 2001. View Article : Google Scholar : PubMed/NCBI

24 

Heo J, Noh OK, Oh YT, Chun M and Kim L: Second primary cancer after liver transplantation in hepatocellular carcinoma: A nationwide population-based study. Hepatol Int. 11:523–528. 2017. View Article : Google Scholar : PubMed/NCBI

25 

Chen Q, Zhao S, Song Y, Gao P, Sun J, Chen X, Sun Y and Wang Z: Do patients with second primary colorectal cancer hold the similar prognosis and therapeutic benefits as those with initial primary colorectal cancer? Biomed Res Int. 2018:Article ID 6172670. 2018. View Article : Google Scholar

Related Articles

Journal Cover

July-2019
Volume 18 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Mao W, Kong M, Yu H, Wang D, Huang X, Yao X, Fan J and Geng J: Prognosis and treatment differences between initial and second primary chondrosarcoma. Oncol Lett 18: 207-218, 2019
APA
Mao, W., Kong, M., Yu, H., Wang, D., Huang, X., Yao, X. ... Geng, J. (2019). Prognosis and treatment differences between initial and second primary chondrosarcoma. Oncology Letters, 18, 207-218. https://doi.org/10.3892/ol.2019.10329
MLA
Mao, W., Kong, M., Yu, H., Wang, D., Huang, X., Yao, X., Fan, J., Geng, J."Prognosis and treatment differences between initial and second primary chondrosarcoma". Oncology Letters 18.1 (2019): 207-218.
Chicago
Mao, W., Kong, M., Yu, H., Wang, D., Huang, X., Yao, X., Fan, J., Geng, J."Prognosis and treatment differences between initial and second primary chondrosarcoma". Oncology Letters 18, no. 1 (2019): 207-218. https://doi.org/10.3892/ol.2019.10329